Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 3, Issue 8, Pages 620-625Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml300042k
Keywords
hypoxia; solid tumors; p300; HIF arylsulfonamide inhibitors; binding model; QSAR; KCN1
Categories
Funding
- EmTechBio
- Southeastern Brain Tumor Foundation
- University Research Council
- NIH [R01 CA86335, CA116804, P30 CA138292, GM084933, GM86925, P50 CA128301]
- V Foundation
- Max Cure Foundation
- Samuel Waxman Cancer Research Foundation
Ask authors/readers for more resources
Hypoxia inducible factors (HIFs) are transcription factors that activate expression of multiple gene products and promote tumor adaptation to a hypoxic environment. To become transcriptionally active, HIFs associate with cofactors p300 or CBP. Previously, we found that arylsulfonamides can antagonize HIP transcription in a bioassay, block the p300/HIF-1 alpha interaction, and exert potent anticancer activity in several animal models. In the present work, KCN1-bead affinity pull down, C-14-labeled KCN1 binding, and KCN1-surface plasmon resonance measurements provide initial support for a mechanism in which KCN1 can bind to the CH1 domain of p300 and likely prevent the p300/HIF-1 alpha assembly. Using a previously reported NMR structure of the p300/HIP-1 alpha complex, we have identified potential binding sites in the p300-CH1 domain. A two-site binding model coupled with IC50 values has allowed establishment of a modest ROC-based enrichment and creation of a guide for future analogue synthesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available